SEARCH

SEARCH BY CITATION

References

  • 1
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP. Treatment of chronic hepatitis C with recombinant Interferon alpha. A multicenter randomized controlled trial. the Hepatitis Interventional therapy group. N Engl J Med 1989; 321:15011506.MEDLINE
  • 2
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murrey L, Waggoner J, Goodman Z, et al. Recombinant Interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:15061510.MEDLINE
  • 3
    Tiné F, Magrin S, Craxi A, Pagliaro L. Interferon in nonA-nonB hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991; 13:192199.MEDLINE
  • 4
    Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski J-P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778789.MEDLINE
  • 5
    Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23:812.MEDLINE
  • 6
    Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, Chu J-S, et al. Long-term efficacy of Ribavirin plus Interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111:13071312.MEDLINE
  • 7
    Reichard O, Norkrans G, Frydén A, Braconier J-H, Sonnerborg A, Weiland O. A randomized double-blind, placebo-controlled trial of Interferon-α2b with and without ribavirin for chronic hepatitis C. for the Swedish Study group Lancet 1998; 351:8387.
  • 8
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432.MEDLINE
  • 9
    McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZH, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:14851492.MEDLINE
  • 10
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:14931499.MEDLINE
  • 11
    Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997; 4:185191.MEDLINE
  • 12
    Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalleto L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26:961966.MEDLINE
  • 13
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. a collaborative Study Group. Ann Intern Med 1995; 122:161168.MEDLINE
  • 14
    Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to Interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19:10881094.MEDLINE
  • 15
    Thiers V, Jaffredo F, Tuveri R, Chodan N, Bréchot C. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests. J Virol Methods 1997; 65:917.MEDLINE
  • 16
    Knodell RG, Ishak KG, Black WG, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5:431435.
  • 17
    NIH Consensus Development Conference. Management of hepatitis C. Hepatology 1997; 26:1S156S.
  • 18
    Chemello L, Bonetti P, Cavaletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22:700706.MEDLINE
  • 19
    DiBisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:897903.MEDLINE
  • 20
    Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337:10581061.MEDLINE
  • 21
    Reichard O, Yun ZB, Sonnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41:99102.MEDLINE
  • 22
    Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, the procoagulant fgl2 prothrombinase and preserves TH1 cytokine production, but inhibits TH2 cytokine response 160. J Immunol 1998; 24:34873493.
  • 23
    Martin J, Navas S, Quiroga JA, Pardo M, Carreno V. Effect of Ribavirin on peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 375:635644.
  • 24
    Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997; 350:970971.MEDLINE
  • 25
    Pol S, Couzigou P, Bourlière M, Abergel A, Combis J-M, Larrey D, Tran A, et al. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non responders to a previous treatment. J Hepatol 1999; 31:17.MEDLINE
  • 26
    Sobesky R, Mathurin P, Charlotte F, Moussali J, Olivi M, Vidaud L, Opolon P, et al. Modeling the impact of Interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116:378386.MEDLINE